Analysts Set Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) PT at $14.50

Shares of Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) have been assigned an average rating of “Hold” from the four analysts that are currently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating and two have issued a buy rating on the company. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $14.50.

VRCA has been the subject of a number of research reports. Zacks Research upgraded shares of Verrica Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Monday, May 11th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Verrica Pharmaceuticals in a research note on Wednesday, July 15th. HC Wainwright began coverage on shares of Verrica Pharmaceuticals in a report on Tuesday, May 26th. They set a “buy” rating and a $12.00 price objective for the company. Finally, Wall Street Zen lowered Verrica Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 15th.

Hedge Funds Weigh In On Verrica Pharmaceuticals

Large investors have recently modified their holdings of the stock. Armistice Capital LLC raised its stake in shares of Verrica Pharmaceuticals by 75.1% in the fourth quarter. Armistice Capital LLC now owns 1,118,925 shares of the company’s stock valued at $9,298,000 after acquiring an additional 479,732 shares during the period. Quadrature Capital Ltd bought a new stake in shares of Verrica Pharmaceuticals in the 4th quarter worth about $99,000. Man Group plc purchased a new position in shares of Verrica Pharmaceuticals during the 4th quarter worth about $94,000. Walleye Capital LLC purchased a new position in shares of Verrica Pharmaceuticals during the 4th quarter worth about $127,000. Finally, Beck Mack & Oliver LLC bought a new position in Verrica Pharmaceuticals during the 4th quarter valued at about $100,000. Institutional investors own 42.45% of the company’s stock.

Verrica Pharmaceuticals Stock Performance

NASDAQ:VRCA opened at $4.91 on Thursday. The stock has a 50-day simple moving average of $5.54 and a two-hundred day simple moving average of $5.82. The firm has a market capitalization of $84.35 million, a PE ratio of -2.94 and a beta of 1.49. The company has a debt-to-equity ratio of 0.18, a quick ratio of 1.33 and a current ratio of 1.45. Verrica Pharmaceuticals has a 52-week low of $3.28 and a 52-week high of $9.82.

About Verrica Pharmaceuticals

Verrica Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of topical therapies for dermatological conditions. Its lead investigational product, VP-102, is a standardized formulation of cantharidin in a pre-measured applicator designed to treat molluscum contagiosum and common warts. Verrica’s approach emphasizes consistency of dosing and patient convenience, aiming to improve upon off‐label use of existing treatments.

Beyond VP-102, Verrica is advancing VP-103, a next‐generation topical candidate intended to optimize tolerability while maintaining efficacy against viral skin lesions.